Skip to main content
Log in

Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Treatments used for managing atopic dermatitis (AD) may have adverse ocular effects that permanently affect vision. The objective of this review is to raise awareness among dermatologists regarding the potential ocular adverse effects of various AD therapies, including corticosteroids, calcineurin inhibitors, an interleukin-4 receptor α (IL-4Rα) antagonist, and phototherapy. Pertinent potential short- and long-term risks of these therapies include elevations in intraocular pressure from use of topical corticosteroids and conjunctivitis from use of dupilumab. Since some of these adverse effects may not exhibit symptomatology until permanent vision impairment occurs, it is important for dermatologists to understand these risks and proactively ensure their patients are receiving appropriate measures to prevent them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Beck KM, Seitzman G, Yang EJ, Sanchez IM, Liao W. Ocular comorbidities of atopic dermatitis. Part I: associated ocular diseases. Am J Clin Dermatol. In Press. https://doi.org/10.1007/s40257-019-00455-5.

  2. Hoare C, Po LWA, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295–9.e27.

    Article  PubMed  Google Scholar 

  4. Turno-Kręcicka A, Grzybowski A, Misiuk-Hojło M, Patryn E, Czajor K, Nita M. Ocular changes induced by drugs commonly used in dermatology. Clin Dermatol. 2016;34(2):129–37.

    Article  PubMed  Google Scholar 

  5. Daniel BS, Orchard D. Ocular side-effects of topical corticosteroids: what a dermatologist needs to know. Australas J Dermatol. 2015;56(3):164–9.

    Article  PubMed  Google Scholar 

  6. Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S. Extensive visual loss with topical facial steroids. Eye (Lond). 1993;7(Pt 5):664–6.

    Article  PubMed  Google Scholar 

  7. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol. 2004;32(2):224–6.

    Article  PubMed  Google Scholar 

  8. Thoe Schwartzenberg GW, Buys YM. Glaucoma secondary to topical use of steroid cream. Can J Ophthalmol. 1999;34(4):222–5.

    CAS  PubMed  Google Scholar 

  9. Michaeli-Cohen A, Neudorfer M, Loewenstein A, Lazar M, Geyer O. Case report: visual loss caused by facial steroids. Can Fam Physician. 1998;44:2462–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Sahni D, Darley CR, Hawk JL. Glaucoma induced by periorbital topical steroid use—a rare complication. Clin Exp Dermatol. 2004;29(6):617–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ross JJ, Jacob A, Batterbury M. Facial eczema and sight-threatening glaucoma. J R Soc Med. 2004;97(10):485–6.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Cubey RB. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br J Dermatol. 1976;95(2):207–8.

    Article  CAS  PubMed  Google Scholar 

  13. Zugerman C, Saunders D, Levit F. Glaucoma from topically applied steroids. Arch Dermatol. 1976;112(9):1326.

    Article  CAS  PubMed  Google Scholar 

  14. Tripathi RC, Parapuram SK, Tripathi BJ, Zhong Y, Chalam KV. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15(6):439–50.

    Article  CAS  PubMed  Google Scholar 

  15. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163–7.

    PubMed  Google Scholar 

  16. Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol. 2011;64(2):275–81.

    Article  CAS  PubMed  Google Scholar 

  17. Tamagawa-Mineoka R, Yasuoka N, Ueta M, Katoh N. Influence of topical steroids on intraocular pressure in patients with atopic dermatitis. Allergol Int. 2018;67(3):388–91.

    Article  CAS  PubMed  Google Scholar 

  18. Haeck IM, Rouwen TJ, Timmer-de Mik L, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J t Am Acad Dermatol. 2011;64(2):275–81.

    Article  CAS  Google Scholar 

  19. Maeng MM, De Moraes CG, Winn BJ, Dagi LRG. Effect of topical periocular steroid use on intraocular pressure: a retrospective analysis. Ophthalmic Plast Reconstr Surg. 2019. https://doi.org/10.1097/IOP.0000000000001320. (Epub 2019 Feb 4).

    Article  PubMed  Google Scholar 

  20. Takakuwa K, Hamanaka T, Mori K, Chin S, Shinmei Y, Funaki T, et al. Atopic glaucoma: clinical and pathophysiological analysis. J Glaucoma. 2015;24(9):662–8.

    Article  PubMed  Google Scholar 

  21. Phulke S, Kaushik S, Kaur S, Pandav S. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11(2):67–72.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70(4):482–91.

    Article  CAS  PubMed  Google Scholar 

  23. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10(3):505–12.

    Article  CAS  PubMed  Google Scholar 

  26. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403–20.

    Article  CAS  PubMed  Google Scholar 

  27. Taniguchi H, Ohki O, Yokozeki H, Katayama I, Tanaka A, Kiyosawa M, et al. Cataract and retinal detachment in patients with severe atopic dermatitis who were withdrawn from the use of topical corticosteroid. J Dermatol. 1999;26(10):658–65.

    Article  CAS  PubMed  Google Scholar 

  28. Katsushima H. Corticosteroid-induced glaucoma following treatment of the periorbital region [in Japanese]. Nippon Ganka Gakkai Zasshi. 1995;99(2):238–43.

    CAS  PubMed  Google Scholar 

  29. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–41.

    Article  PubMed  Google Scholar 

  30. Nagaki Y, Hayasaka S, Kadoi C. Cataract progression in patients with atopic dermatitis. J Cataract Refract Surg. 1999;25(1):96–9.

    Article  CAS  PubMed  Google Scholar 

  31. Jeon HS, Choi M, Byun SJ, Hyon JY, Park KH, Park SJ. Association of pediatric atopic dermatitis and cataract development and surgery. JAMA Ophthalmol. 2018;136(8):912–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Oglesby RB, Black RL, Von Sallmann L, Bunim JJ. Cataracts in rheumatoid arthritis patients treated with corticosteroids. Description and differential diagnosis. Arch Ophthalmol. 1961;66:519–23.

    CAS  PubMed  Google Scholar 

  33. Oka C, Ideta H, Nagasaki H, Watanabe K, Shinagawa K. Retinal detachment with atopic dermatitis similar to traumatic retinal detachment. Ophthalmology. 1994;101(6):1050–4.

    Article  CAS  PubMed  Google Scholar 

  34. Ricketti PA, Unkle DW, Cleri DJ, Prenner JL, Coluccielo M, Ricketti AJ. Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease. Allergy Asthma Proc. 2015;36(2):123–9.

    Article  CAS  PubMed  Google Scholar 

  35. Thyssen J, de Bruin-Weller M, Paller A, Leshem Y, Vestergaard C, Deleuran M, et al. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy–International Eczema Council survey and opinion. J Eur Acad Dermatol Venereol. 2019;33(7):1224–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.

    Article  CAS  PubMed  Google Scholar 

  37. Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–11.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson E, Blauvelt A, Cork M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.17869. (Epub 2019 Mar 9).

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegraber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778–1780.e1.

    Article  PubMed  Google Scholar 

  40. Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120–2.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Yamane MLM, Belsito DV, Glass LRD. Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis. Orbit. 2019;10:1–5.

    Google Scholar 

  42. Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154(12):1485–6.

    Article  PubMed  Google Scholar 

  43. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.

    Article  CAS  PubMed  Google Scholar 

  44. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.

    Article  CAS  PubMed  Google Scholar 

  45. Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303–10.

    Article  CAS  PubMed  Google Scholar 

  46. Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280–86.e1.

    Article  PubMed  Google Scholar 

  47. Mennini M, Dahdah L, Fiocchi A. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis [letter]. N Engl J Med. 2017;376(11):1090.

    Article  PubMed  Google Scholar 

  48. Shen E, Xie K, Jwo K, Smith J, Mosaed S. Dupilumab-induced follicular conjunctivitis. Ocular Immunol Inflammn. 2018. https://doi.org/10.1080/09273948.2018.1533567. (Epub 2018 Oct 18).

    Article  Google Scholar 

  49. Bakker D, Ariens L, van Luijk C, van der Schaft J, Thijs J, Schuttelaar M, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis [letter]. Br J Dermatol. 2019;180(5):1248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. de Bruin-Weller M, Graham NMH, Pirozzi G, Shumel B. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Reply from the authors [letter]. Br J Dermatol. 2018;178(5):1220–1.

    Article  PubMed  Google Scholar 

  51. Gooderham M, McDonald J, Papp K. Diagnosis and management of conjunctivitis for the dermatologist. J Cutan Med Surg. 2018;22(2):200–6.

    Article  PubMed  Google Scholar 

  52. Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66–80.

    Article  CAS  PubMed  Google Scholar 

  53. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol. 2003;135(3):297–302.

    Article  CAS  PubMed  Google Scholar 

  54. Murrell DF, Calvieri S, Ortonne JP, Ho VC, Weise-Riccardi S, Barbier N, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157(5):954–9.

    Article  CAS  PubMed  Google Scholar 

  55. Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(s2):4–9.

    Article  PubMed  Google Scholar 

  56. Barot RK, Shitole SC, Bhagat N, Patil D, Sawant P, Patil K. Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases. J Clin Diagn Res. 2016;10(6):Nc05–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol. 2014;157(2):280–6.

    Article  CAS  PubMed  Google Scholar 

  58. Freeman AK, Serle J, VanVeldhuisen P, Lind L, Clarke J, Singer G, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis. 2004;73(4):267–71.

    PubMed  Google Scholar 

  59. Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013;92(5):258–63.

    PubMed  Google Scholar 

  60. Nivenius E, van der Ploeg I, Jung K, Chryssanthou E, van Hage M, Montan PG. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis. Eye (Lond). 2007;21(7):968–75.

    Article  CAS  PubMed  Google Scholar 

  61. Sakarya Y, Sakarya R. Treatment of refractory atopic blepharoconjunctivitis with topical tacrolimus 0.03% dermatologic ointment. J Ocul Pharmacol Ther. 2012;28(1):94–6.

    Article  CAS  PubMed  Google Scholar 

  62. Boguniewicz M, Nicol N, Kelsay K, Leung DY. A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg. 2008;27(2):115–27.

    Article  CAS  PubMed  Google Scholar 

  63. Lübbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology. 2000;201(3):249–51.

    Article  PubMed  Google Scholar 

  64. Kiiski V, Remitz A, Reitamo S, Mandelin J, Kari O. Long-term safety of topical pimecrolimus and topical tacrolimus in atopic blepharoconjunctivitis. JAMA Dermatol. 2014;150(5):571–3.

    Article  PubMed  Google Scholar 

  65. Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (Lond). 2017;9(4):7.

    Article  Google Scholar 

  66. Small DS, Acheampong A, Reis B, Stern K, Stewart W, Berdy G, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002;18(5):411–8.

    Article  CAS  PubMed  Google Scholar 

  67. Gonzalez-Lopez JJ, Lopez-Alcalde J, Morcillo Laiz R, Fernandez Buenaga R, Rebolleda Fernandez G. Topical cyclosporine for atopic keratoconjunctivitis. Cochrane Database Syst Rev. 2012;9:CD009078.

    Google Scholar 

  68. Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol. 2014;98(8):1023–7.

    Article  PubMed  Google Scholar 

  69. Erdinest N, Solomon A. Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol. 2014;14(5):457–63.

    Article  CAS  PubMed  Google Scholar 

  70. Wan KH, Chen LJ, Rong SS, Pang CP, Young AL. Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis. Ophthalmology. 2013;120(11):2197–203.

    Article  PubMed  Google Scholar 

  71. NEORAL (cyclosporine) [package insert]. East Hanover: Novartis Pharmaceuticals Corporation. 2015.

  72. SANDIMMUNE (cyclosporine) [package insert]. East Hanover: Novartis Pharmaceuticals Corporation. 2015.

  73. RESTASIS (cyclosporine ophthalmic emulsion) [package insert]. 0.05%. Irvine: Allergan. 2017.

  74. Rouimi F, Bouillot A, Baudouin C, Labbe A. Topical cyclosporine A and risk of ocular surface neoplasia [in French]. J Fr Ophtalmol. 2018;41(2):122–8.

    Article  CAS  PubMed  Google Scholar 

  75. Brenner W, Grabner G. 3H-thymidine autoradiography of guinea pig cornea and skin after exposure to solar simulating radiation. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;216(4):319–25.

    Article  CAS  PubMed  Google Scholar 

  76. De Pry J, Brescoll J, Szczotka-Flynn L, Rambhatla P, Lim HW, Cooper K. Phototherapy-related ophthalmologic disorders. Clin Dermatol. 2015;33(2):247–55.

    Article  Google Scholar 

  77. Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):22–31.

    Article  CAS  PubMed  Google Scholar 

  78. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–49.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Calzavara-Pinton PG, Carlino A, Manfredi E, Semeraro F, Zane C, De Panfilis G. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol Suppl (Stockh). 1994;186:164–5.

    CAS  PubMed  Google Scholar 

  80. Abdullah AN, Keczkes K. Cutaneous and ocular side-effects of PUVA photochemotherapy—a 10-year follow-up study. Clin Exp Dermatol. 1989;14(6):421–4.

    Article  CAS  PubMed  Google Scholar 

  81. Glew WB, Nigra TP. Psoralens and ocular effects in humans. Natl Cancer Inst Monogr. 1984;66:235–9.

    CAS  PubMed  Google Scholar 

  82. Richer SP, Yonatan E, Harper CK, McNelis M, Rudy DR, Perdue A. A clinical review of non-age-related cataracts. Optometry. 2001;72(12):767–78.

    CAS  PubMed  Google Scholar 

  83. Bair B, Dodd J, Heidelberg K, Krach K. Cataracts in atopic dermatitis: a case presentation and review of the literature. Arch Dermatol. 2011;147(5):585–8.

    Article  PubMed  Google Scholar 

  84. Malanos D, Stern RS. Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol. 2007;57(2):231–7.

    Article  PubMed  Google Scholar 

  85. Stern RS, Parrish JA, Fitzpatrick TB. Ocular findings in patients treated with PUVA. J Invest Dermatol. 1985;85(3):269–73.

    Article  CAS  PubMed  Google Scholar 

  86. Stern RS. Ocular lens findings in patients treated with PUVA. Photochemotherapy follow-up-study. J Invest Dermatol. 1994;103(4):534–8.

    Article  CAS  PubMed  Google Scholar 

  87. Maitray A, Rishi P. Methoxsalen-induced macular toxicity. Indian J Ophthalmol. 2017;65(11):1243–5.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Soker S, Nergiz Y, Cakmak S, Bahceci S, Aytekin S. The demonstration of changes in bulbar conjunctiva surface epithelium in the psoriatic patients treated with PUVA. Ann Ophthalmol (Skokie). 2008;40(2):94–8.

    PubMed  Google Scholar 

  89. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997;336(15):1041–5.

    Article  CAS  PubMed  Google Scholar 

  90. Haciyakupoglu G, Varinli I, Memisoglu HR, Varinli S, Demircan N, Denli G. PUVA treatment and choroidal malignant melanoma. Acta Ophthalmol (Copenh). 1993;71(6):846–9.

    Article  CAS  PubMed  Google Scholar 

  91. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e6.

    Article  CAS  PubMed  Google Scholar 

  92. Baeck M, De Potter P, Goossens A. Allergic contact dermatitis following ocular use of corticosteroids. J Ocul Pharmacol Ther. 2011;27(1):83–92.

    Article  CAS  PubMed  Google Scholar 

  93. Mimesh S, Pratt M. Allergic contact dermatitis from corticosteroids: reproducibility of patch testing and correlation with intradermal testing. Dermatitis. 2006;17(3):137–42.

    Article  PubMed  Google Scholar 

  94. Shaw DW, Maibach HI, Eichenfield LF. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy. J Am Acad Dermatol. 2007;56(2):342–5.

    Article  PubMed  Google Scholar 

  95. Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94(1):134–6.

    Article  CAS  PubMed  Google Scholar 

  96. Chisholm SAM, Couch SM, Custer PL. Etiology and management of allergic eyelid dermatitis. Ophthalmic Plast Reconstr Surg. 2017;33(4):248–50.

    Article  PubMed  Google Scholar 

  97. Bielory L. Allergic conjunctivitis: the evolution of therapeutic options. Allergy Asthma Proc. 2012;33(2):129–39.

    Article  CAS  PubMed  Google Scholar 

  98. Ousler GW, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther. 2007;29(4):611–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kristen M. Beck.

Ethics declarations

Funding

This article has no funding source.

Conflict of interest

Kristen M. Beck, Gerami D. Seitzman, Eric J. Yang, and Isabelle M. Sanchez have no conflicts of interest to declare. Wilson Liao has received a research grant from Sanofi/Regeneron, which manufactures dupilumab. Sanofi/Regeneron was not involved in the content, writing, or review of this manuscript.

Prior presentation

This work has not been previously presented.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beck, K.M., Seitzman, G.D., Yang, E.J. et al. Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments. Am J Clin Dermatol 20, 807–815 (2019). https://doi.org/10.1007/s40257-019-00465-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-019-00465-3

Navigation